174 related articles for article (PubMed ID: 23833241)
1. Significant increase in plasma 4β-hydroxycholesterol concentration in patients after kidney transplantation.
Suzuki Y; Itoh H; Sato F; Kawasaki K; Sato Y; Fujioka T; Sato Y; Ohno K; Mimata H; Kishino S
J Lipid Res; 2013 Sep; 54(9):2568-72. PubMed ID: 23833241
[TBL] [Abstract][Full Text] [Related]
2. Association of plasma concentration of 4β-hydroxycholesterol with CYP3A5 polymorphism and plasma concentration of indoxyl sulfate in stable kidney transplant recipients.
Suzuki Y; Itoh H; Fujioka T; Sato F; Kawasaki K; Sato Y; Sato Y; Ohno K; Mimata H; Kishino S
Drug Metab Dispos; 2014 Jan; 42(1):105-10. PubMed ID: 24135442
[TBL] [Abstract][Full Text] [Related]
3. Factors involved in phenoconversion of CYP3A using 4β-hydroxycholesterol in stable kidney transplant recipients.
Suzuki Y; Muraya N; Fujioka T; Sato F; Tanaka R; Matsumoto K; Sato Y; Ohno K; Mimata H; Kishino S; Itoh H
Pharmacol Rep; 2019 Apr; 71(2):276-281. PubMed ID: 30826567
[TBL] [Abstract][Full Text] [Related]
4. CYP3A5 polymorphism affects the increase in CYP3A activity after living kidney transplantation in patients with end stage renal disease.
Suzuki Y; Fujioka T; Sato F; Matsumoto K; Muraya N; Tanaka R; Sato Y; Ohno K; Mimata H; Kishino S; Itoh H
Br J Clin Pharmacol; 2015 Dec; 80(6):1421-8. PubMed ID: 26773964
[TBL] [Abstract][Full Text] [Related]
5. Pretransplant 4β-hydroxycholesterol does not predict tacrolimus exposure or dose requirements during the first days after kidney transplantation.
Vanhove T; Hasan M; Annaert P; Oswald S; Kuypers DRJ
Br J Clin Pharmacol; 2017 Nov; 83(11):2406-2415. PubMed ID: 28603840
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of 4β-Hydroxycholesterol and 25-Hydroxycholesterol as Endogenous Biomarkers of CYP3A4: Study with CYP3A-Humanized Mice.
Nitta SI; Hashimoto M; Kazuki Y; Takehara S; Suzuki H; Oshimura M; Akita H; Chiba K; Kobayashi K
AAPS J; 2018 Apr; 20(3):61. PubMed ID: 29858698
[TBL] [Abstract][Full Text] [Related]
7. The CYP3A biomarker 4β-hydroxycholesterol does not improve tacrolimus dose predictions early after kidney transplantation.
Størset E; Hole K; Midtvedt K; Bergan S; Molden E; Åsberg A
Br J Clin Pharmacol; 2017 Jul; 83(7):1457-1465. PubMed ID: 28146606
[TBL] [Abstract][Full Text] [Related]
8. CYP3A activity based on plasma 4β-hydroxycholesterol during the early postpartum period has an effect on the plasma disposition of amlodipine.
Naito T; Kubono N; Ishida T; Deguchi S; Sugihara M; Itoh H; Kanayama N; Kawakami J
Drug Metab Pharmacokinet; 2015 Dec; 30(6):419-24. PubMed ID: 26654672
[TBL] [Abstract][Full Text] [Related]
9. Sensitive UHPLC-MS/MS quantification method for 4β- and 4α-hydroxycholesterol in plasma for accurate CYP3A phenotyping.
Suzuki Y; Oda A; Negami J; Toyama D; Tanaka R; Ono H; Ando T; Shin T; Mimata H; Itoh H; Ohno K
J Lipid Res; 2022 Mar; 63(3):100184. PubMed ID: 35181316
[TBL] [Abstract][Full Text] [Related]
10. Assessment of induced CYP3A activity in pregnant women using 4β-hydroxycholesterol: Cholesterol ratio as an appropriate metabolic marker.
Kim AH; Kim B; Rhee SJ; Lee Y; Park JS; Lee SM; Kim SM; Lee S; Yu KS; Jang IJ; Cho JY
Drug Metab Pharmacokinet; 2018 Jun; 33(3):173-178. PubMed ID: 29759884
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the usefulness of plasma 4β-hydroxycholesterol concentration normalized by 4α-hydroxycholesterol for accurate CYP3A phenotyping.
Oda A; Suzuki Y; Sato H; Koyama T; Nakatochi M; Momozawa Y; Tanaka R; Ono H; Tatsuta R; Ando T; Shin T; Wakai K; Matsuo K; Itoh H; Ohno K
Clin Transl Sci; 2024 Mar; 17(3):e13768. PubMed ID: 38465776
[TBL] [Abstract][Full Text] [Related]
12. CYP3A induction and inhibition by different antiretroviral regimens reflected by changes in plasma 4beta-hydroxycholesterol levels.
Josephson F; Bertilsson L; Böttiger Y; Flamholc L; Gisslén M; Ormaasen V; Sönnerborg A; Diczfalusy U
Eur J Clin Pharmacol; 2008 Aug; 64(8):775-81. PubMed ID: 18458892
[TBL] [Abstract][Full Text] [Related]
13. 4Beta-hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians.
Diczfalusy U; Miura J; Roh HK; Mirghani RA; Sayi J; Larsson H; Bodin KG; Allqvist A; Jande M; Kim JW; Aklillu E; Gustafsson LL; Bertilsson L
Pharmacogenet Genomics; 2008 Mar; 18(3):201-8. PubMed ID: 18300941
[TBL] [Abstract][Full Text] [Related]
14. 4β-Hydroxycholesterol as an Endogenous Biomarker for CYP3A Activity: Literature Review and Critical Evaluation.
Penzak SR; Rojas-Fernandez C
J Clin Pharmacol; 2019 May; 59(5):611-624. PubMed ID: 30748026
[TBL] [Abstract][Full Text] [Related]
15. Recovery of CYP3A Phenotype after Kidney Transplantation.
Hole K; Størset E; Olastuen A; Haslemo T; Kro GB; Midtvedt K; Åsberg A; Molden E
Drug Metab Dispos; 2017 Dec; 45(12):1260-1265. PubMed ID: 28928137
[TBL] [Abstract][Full Text] [Related]
16. 4β-Hydroxycholesterol as an endogenous biomarker of CYP3A activity in cynomolgus monkeys.
Li K; Zhao S; Zhang L; Wu X; Shu P; Wang Y; Feng H; Gu Z; Han Hsu H
Drug Metab Dispos; 2014 May; 42(5):839-43. PubMed ID: 24595680
[TBL] [Abstract][Full Text] [Related]
17. Sex and CYP3A5 genotype influence total CYP3A activity: high CYP3A activity and a unique distribution of CYP3A5 variant alleles in Ethiopians.
Gebeyehu E; Engidawork E; Bijnsdorp A; Aminy A; Diczfalusy U; Aklillu E
Pharmacogenomics J; 2011 Apr; 11(2):130-7. PubMed ID: 20231858
[TBL] [Abstract][Full Text] [Related]
18. 4β-Hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans.
Diczfalusy U; Nylén H; Elander P; Bertilsson L
Br J Clin Pharmacol; 2011 Feb; 71(2):183-9. PubMed ID: 21219398
[TBL] [Abstract][Full Text] [Related]
19. Use of 4β-Hydroxycholesterol Plasma Concentrations as an Endogenous Biomarker of CYP3A Activity: Clinical Validation in Individuals With Type 2 Diabetes.
Gravel S; Chiasson JL; Gaudette F; Turgeon J; Michaud V
Clin Pharmacol Ther; 2019 Oct; 106(4):831-840. PubMed ID: 31002385
[TBL] [Abstract][Full Text] [Related]
20. Perspective: 4β-hydroxycholesterol as an emerging endogenous biomarker of hepatic CYP3A.
Mao J; Martin I; McLeod J; Nolan G; van Horn R; Vourvahis M; Lin YS
Drug Metab Rev; 2017 Feb; 49(1):18-34. PubMed ID: 27718639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
